TG4010: Clinical Trials

3 trials of TG4010, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Terminated 1
Phase 31Terminated 1

Follow TG4010: new trials by email Literature Review of TG4010 trials Research Report on TG4010

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
TG4010, Chemotherapy, Nivolumab - Non Small Cell Lung Cancer Metastatic
Phase 2CompletedTransgene442018-01-052022-01-11
TG4010 and Nivolumab in Patients With Lung Cancer
TG4010, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
Phase 2CompletedMegan Daly, MD132016-12-142025-11-10
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
TG4010, placebo - Non-Small-Cell Lung Carcinoma
Phase 2 / Phase 3TerminatedTransgene2222012-04-012017-01-05

Conditions studied

Carcinoma, Non-Small-Cell Lung (3)

Sponsors

Transgene (2)  ·  Megan Daly, MD (1)

Countries

United States (3)  ·  Belgium (2)  ·  France (2)  ·  Hungary (2)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Karen Kelly (1)

Results publications

PMID 26727163, PMID 28923084

NIH funding

P30CA093373 (1)